Global Hodgkin Lymphoma Treatment Market Size

Hodgkins Lymphoma Treatment Market Analysis

The Hodgkin lymphoma (HL) treatment market is expected to register a CAGR of 12.5% during the forecast period.

Patients with Hodgkin lymphoma are at a higher risk for SARS-CoV-2 infection as they typically receive immunosuppressive and chemotherapy drugs during treatment. For instance, in November 2021, a research study published by the Baishideng Publishing Group Inc. stated that patients with lymphoma appeared particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Furthermore, according to the same source, there is an increased risk of COVID-19-related serious events (ICU admission, mechanical ventilation support, or death) in patients with lymphomas as compared to COVID-19 patients without cancer and confirms the high vulnerability of such patients in the current pandemic. Hence, with the vulnerability of Hodgkin lymphoma to COVID-19, the need for its treatment has increased, driving the growth of the market. Additionally, there is better access to treatment as compared to the initial pandemic phase due to the lockdown, the market has reached its pre-pandemic level growth and is expected to grow significantly over the forecast period.

The growing burden of Hodgkin lymphoma as well as increasing awareness about it and high unmet needs in older patients and patients with relapsed or refractory (R/R) HL are key factors expected to drive the market over the forecast period. For instance, according to a CDC update in September 2022, the estimated 5-year limited duration prevalence counts for Hodgkin Lymphoma, is 38,289 out of which 17,437 are female and 20,851 are male. Various research studies on the efficacy of better treatments have been conducted. For instance, in June 2022, a research study published by the Journal of Clinical Oncology stated that the anti-CD30 antibody-drug conjugate, Brentuximab vedotin (Bv) is approved for adults with advanced-stage HL but its use has not been established in children or adolescents. Brentuximab vedotin with AVE-PC in a dose-intensive regimen has superior efficacy to ABVE-PC for pediatric patients with high-risk HL. A 59% risk reduction in EFS was achieved with no increase in toxicity. Such development is expected to drive the growth of the market over the forecast period.

Several biopharmaceutical companies are seeking approval for the advancement of Hodgkin lymphoma to improve the treatment which is expected to drive the market growth over the forecast period. For instance, in November 2022, the FDA approved brentuximab vedotin (Adcetris, Seagen, Inc.) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients two years of age and older with previously untreated high-risk classical Hodgkin lymphoma (cHL). This is the first pediatric approval for brentuximab vedotin.

Hence, various ongoing studies on HL to provide better treatment options and product approval is contributing to the overall market growth. However, adverse long-term side effects and the high cost of treatment are expected to restrain the growth of the Hodgkin lymphoma treatment market.